Form 4: Sutro Biopharma Director Sukhi Jagpal Granted 50,000 Stock Options

Sutro Biopharma, Inc. Director Sukhi Jagpal was granted 50,000 stock options with an exercise price of $0.85, vesting over approximately one year.

Summary

• Sukhi Jagpal, a Director of Sutro Biopharma, Inc. (STRO), was granted 50,000 stock options.
• The options have an exercise price of $0.85 per share.
• The transaction date for the grant was June 6, 2025.
• The options begin vesting on July 6, 2025, at a rate of 8.33% of the total shares monthly.
• Full vesting (100%) will occur on the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026.
• Vesting is contingent upon Sukhi Jagpal's continued provision of service to Sutro Biopharma.
• The options expire on June 6, 2035.
• Following this transaction, Sukhi Jagpal directly beneficially owns 50,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director aligns their interests with shareholders, indicating continued commitment to the company, which is generally viewed positively for corporate governance and long-term strategy.

Positives

• The grant of stock options to Director Sukhi Jagpal aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period (until June 6, 2035), providing a long-term incentive.

Risks

• The value of the stock options is dependent on the future performance of Sutro Biopharma's common stock, which is subject to market fluctuations and company-specific risks.
• Vesting is subject to continued service, meaning the options could be forfeited if the director's service ceases before full vesting.

Future Outlook

The vesting schedule indicates that Director Sukhi Jagpal is expected to continue providing service to Sutro Biopharma, Inc. for at least the next year to fully vest the granted stock options.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industries, commonly used to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• Equity compensation, such as stock options, is a prevalent component of executive and director compensation packages across the biotechnology sector, including companies like Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD), though specific grant sizes and vesting schedules vary based on individual roles, company size, and performance.
• The 10-year expiration period for the options is a common industry standard for long-term incentive grants.
• The monthly vesting schedule over approximately one year is also a typical approach for director equity grants, ensuring continued engagement.

Related Party Transactions

• The grant of 50,000 stock options to Sukhi Jagpal, a Director of Sutro Biopharma, Inc., constitutes a related party transaction, which is a standard form of equity compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Director (Sukhi Jagpal): Receives a significant equity incentive, contingent on continued service and company performance.

Next Steps

• Director Sukhi Jagpal's continued provision of service to Sutro Biopharma, Inc. for the options to fully vest.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, stock options, insider transaction, director, equity compensation, beneficial ownership